Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 1251 results for public health guidance

  1. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  2. Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date:  23 September 2027

    Technology appraisal guidance
    Awaiting development

  3. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]

    Awaiting development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]

    Awaiting development Reference number: GID-TA11877 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]

    Awaiting development Reference number: GID-TA11489 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Awaiting development Reference number: GID-TA11956 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  14. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    Awaiting development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development